Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy

British Journal of Cancer

Volumn 109, Issue 9, 2013, Pages 2481-2488

  Chang, K C ^a   Wu, Y Y ^b   Hung, C H ^a   Lu, S N ^a   Lee, C M ^a   Chiu, K W ^a   Tsai, M C ^a   Tseng, P L ^a   Huang, C M ^c   Cho, C L ^a   Chen, H H ^b   Hu, T H ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

hepatitis C virus; hepatocellular carcinoma; interferon; risk score

Indexed keywords

ALPHA FETOPROTEIN; ALPHA2B INTERFERON; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; REBETOLS; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CHRONIC PATIENT; COHORT ANALYSIS; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK REDUCTION; SCORING SYSTEM; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE COUNT; TREATMENT RESPONSE;

EID: 84887020913     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.564     Document Type: Article

References (37)

1. Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, Takahashi S, Ohishi W, Arihiro K, Kubo M, Nakamura Y, Chayama K (2010) Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 53: 439-443.
2. Amarapurkar D, Han KH, Chan HL, Ueno Y. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma (2009) Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. J Gastroenterol Hepatol 24: 955-961.
3. Andersson KL, Salomon JA, Goldie SJ, Goldie SJ, Chung RT (2008) Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 6: 1418-1424.
4. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N (2010) Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus Infection. Hepatology 52: 518-527.
5. Bruix J, Sherman M. American Association for the Study of Liver Diseases (2005) Management of hepatocellular carcinoma-An update. Hepatology 42: 1208-1236.
6. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU (2007) Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: A seventeen-year prospective cohort study. Hepatology 46: 1350-1356.
7. Chen CH, Wang MH, Wang JH, Hung CH, Hu TH, Lee SC, Tung HD, Lee CM, Changchien CS, Chen PF, Hsu MC, Lu SN (2007) Aflatoxin exposure and hepatitis C virus in advanced liver disease in a hepatitis C virus endemic area in Taiwan. Am J Trop Med Hyg 77: 747-752.
8. Craxi A, Camma C (2005) Prevention of hepatocellular carcinoma. Clin Liver Dis 9: 329-346.
9. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ (1994) Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19: 1513-1520.
10. Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ (2008) Des-g-carboxyprothrombin, a-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 23: 1541-1548.
11. El-Serag HB (2004) Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology 127: S27-S34.
12. European Association for the Study of the Liver (2011) EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 55: 245-264.
13. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, Cmet S, Fornasiere E, Fumolo E, Fangazio S, Cerutti A, Minisini R, Pirisi M, Toniutto P (2011) IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: Role in the course of chronic viral hepatitis and the development of HCC. J Hepatol 54: 716-722.
14. Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 127: S35-S50.
15. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales Jr. FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl J Med 347: 975-982.
16. Hadziyannis SJ, Sette Jr. H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer Jr. H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM (2004) Peginterferon-Alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355.
17. Hung CH, Chen CH, Lee CM, Wu CM, Hu TH, Wang JH, Yen YH, Lu SN (2008) Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma. J Viral Hepat 15: 58-65.
18. Hung CH, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, Lu SN (2011) Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer 128: 2344-2352.
19. Kubo S, Tanaka H, Shuto T, Takemura S, Yamamoto T, Uenishi T, Tanaka S, Ogawa M, Sakabe K, Yamazaki K, Hirohashi K (2004) Correlation between low platelet count and multicentricity of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatol Res 30: 221-225.
20. Lavanchy D (2009) The global burden of hepatitis C. Liver Int 29: 74-81.
21. Lee CM, Hung CH, Lu SN, Changchien CS (2008) Hepatitis C virus genotypes: Clinical relevance and therapeutic implications. Chang Gung Med J 31: 16-25.
22. Lee MH, Yamg HI, Lu SN, Jen CL, You SL, Wang LY, Yuan Y, Litalien G, Chen CJ (2012) Clinical scoring prediction of long-Term risk for hepatocellular carcinoma among hepatitis C virus infected patients. Hepatol Internal 6: 22-43.
23. Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, Chen PJ, You SL, Wang LY, Chen WJ, Chen CJ (2010) Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: Long-Term predictors from a community-based cohort study. J Clin Oncol 28: 4587-4593.
24. Lu SN, Wang JH, Liu SL, Hung CH, Chen CH, Tung HD, Chen TM, HuangWS, Lee CM, Chen CC, Changchien CS (2006) Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 107: 2212-2222.
25. Mallat A, Hezode C, Lotersztajn S (2008) Environmental factors as disease accelerators during chronic hepatitis C. J Hepatol 48: 657-665.
26. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 358: 958-965.
27. Marc G, Ghany MG, Nelson DR, Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. American Association for Study of Liver Diseases (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54(4): 1433-1444.
28. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485-1492.
29. Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H, Nakamura S, Kobayashi Y, Araki Y, Aoki N, Shiratori Y (2008) Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol 23: 437-444.
30. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, JafriW, Chow P, LimSG, Chawla YK, BudihusodoU, Gani RA, LesmanaCR, Putranto TA, Liaw YF, Sarin SK (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4: 439-474.
31. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ (2001) Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: A meta-Analysis. Aliment Pharmacol Ther 15: 689-698.
32. Rahman El-Zayadi A, Abaza H, Shawky S, Mohamed MK, Selim OE, Badran HM (2001) Prevalence and epidemiological features of hepatocellular carcinoma in Egypt - A single center experience. Hepatol Res 19: 170-179.
33. Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, Baba Y, Imamura Y, Aikou T (2001) Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients: Cancer of the Liver Italian Program. Hepatology 34: 529-534.
34. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL (2007) Sustained virological response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147: 677-684.
35. Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, Chen CJ (2010) Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B Virus Infection. J Clin Oncol 28: 2437-2444.
36. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, Chen CJ, Wong VW, Seto WK. REACH-B Working Group (2011) Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score. Lancet Oncol 12: 568-574.
37. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, But DY, Chan AO, Wong BC, Mizokami M, Lai CL (2009) Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 50: 80-88.